No 'Constraining Situation' On Generic Vascepa API, Says Strides MD

Q3 Revenues Jump; Generic Suprep Likely To Be Launched In Q4

 
• By Vibha Ravi

Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business.

Earnings Concept
Strides Reported A Strong Third Quarter And Expects Generic Vascepa To Add Momentum • Source: Shutterstock

More from Strategy

More from Business